Affinage

ERG

Transcriptional regulator ERG · UniProt P11308

Length
479 aa
Mass
53.8 kDa
Annotated
2026-06-09
100 papers in source corpus 41 papers cited in narrative 40 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ERG is an ETS-family sequence-specific transcription factor that orchestrates lineage-defining transcriptional programs in vascular endothelium, hematopoiesis, and skeletal development, and is co-opted as a dominant oncogenic driver when structurally rearranged (PMID:3476934, PMID:1766675, PMID:18283340). Its DNA-binding ETS domain is allosterically autoinhibited by flanking regions that quench Ets-domain conformational dynamics, a regulatory switch relieved by EZH2-mediated methylation of K362 within the internal autoinhibitory domain to favor DNA binding and transactivation (PMID:23898196, PMID:34230470). In the vasculature ERG directly transactivates VE-cadherin to maintain endothelial cell-cell junctions and survival, supports angiogenesis, and represses endothelin-1 secretion, thereby restraining paracrine fibroblast activation and cardiac/lung fibrosis; combined loss with FLI1 drives endothelial-to-mesenchymal transition (PMID:18195090, PMID:33469864, PMID:30500808, PMID:35879310). In hematopoiesis ERG drives megakaryopoiesis, cooperates with the GATA1s mutant to immortalize progenitors, supports B-lymphoid differentiation upstream of Ebf1/Pax5 and V(D)J recombination, and is the principal transcriptional effector of EVI1-driven AML (PMID:19487285, PMID:19168790, PMID:32541654, PMID:36095844). When fused (TMPRSS2-ERG, EWS-ERG, FUS/TLS-ERG), ERG reprograms transcription: it retargets BAF/SWI-SNF chromatin remodeling complexes genome-wide, redirects AR to cryptic enhancers and sustains AR coregulator (NCOA3) and Pol II occupancy, orchestrates 3D chromatin looping to silence the Trp63 enhancer and suppress basal differentiation, and directly activates or represses targets including SOX9, YAP1 (with KDM4A), the sGC α1/β1 subunits, TFF3, PIM1, ANXA2, and TDRD1 to promote invasion and proliferation (PMID:30078722, PMID:32934023, PMID:32701507, PMID:23426182, PMID:26058078, PMID:30718921). The TLS-ERG fusion instead acts through RNA Pol II binding while failing to recruit SR splicing factors, causing aberrant, cell-type-specific RNA splicing (PMID:10779324, PMID:15988032). ERG protein abundance is tightly controlled by ubiquitin-proteasomal degradation through the SPOP/CRL3 adaptor recognizing an N-terminal degron and through GSK3β/WEE1 dual phosphorylation (T187/Y190) that recruits FBW7, pathways exploited by truncated fusions that escape degron-dependent turnover (PMID:26344095, PMID:26344096, PMID:32871104).

Mechanistic history

Synthesis pass · year-by-year structured walk · 24 steps
  1. 1987 High

    Establishing the molecular identity of ERG answered whether it was a distinct gene, defining it as a member of the ETS oncogene family separate from ets1/ets2.

    Evidence cDNA cloning, sequencing, and Northern blot

    PMID:3476934

    Open questions at the time
    • Did not define DNA-binding specificity or transcriptional function
    • No cellular role assigned
  2. 1991 High

    Showing ERG isoforms bind DNA sequence-specifically and transactivate reporters established ERG as a bona fide transcription factor rather than merely an ETS-homologous ORF.

    Evidence Recombinant protein DNA-binding and transactivation reporter assays

    PMID:1766675

    Open questions at the time
    • Physiological target genes unknown
    • Tissue context undefined
  3. 1994 Medium

    Identifying EWS-ERG fusion in Ewing's sarcoma revealed that ERG's ETS domain becomes oncogenic through structural fusion, the first cancer alteration of ERG.

    Evidence Cytogenetics and RT-PCR in a cell line

    PMID:8076344

    Open questions at the time
    • Single cell line, no mechanistic dissection of fusion activity
    • Target genes of fusion not defined
  4. 2000 High

    Dissecting the TLS-ERG fusion answered how it transforms, revealing that the ERG portion displaces TLS SR splicing-factor recruitment to cause aberrant splicing while retaining Pol II binding.

    Evidence Co-IP, in-cell splicing assays, deletion analysis in K562 cells

    PMID:10779324

    Open questions at the time
    • In vivo leukemogenesis not shown
    • Full set of mis-spliced transcripts unknown
  5. 2005 High

    Comparing TLS-ERG effects across cell lines established that its transcriptional/splicing consequences are cell-type-specific, mapping Pol II binding to the N-terminal 173 residues.

    Evidence Deletion mutants, reporter and splicing assays, microarrays in two cell lines

    PMID:15988032

    Open questions at the time
    • Determinants of cell-type specificity not identified
    • Primary patient relevance untested
  6. 2008 High

    Identifying VE-cadherin as a direct ERG target answered how ERG maintains the endothelium, linking ERG to junctional integrity, survival, and angiogenesis.

    Evidence ChIP, knockdown/rescue, in vivo Matrigel plug, caspase staining

    PMID:18195090

    Open questions at the time
    • Full endothelial target network not mapped
    • Upstream regulators of ERG in EC unknown
  7. 2008 High

    Linking TMPRSS2-ERG to an invasion program and PIN in transgenic mice established ERG fusion as a driver of prostate oncogenesis via the plasminogen activation pathway.

    Evidence Transgenic mice, gain/loss-of-function in prostate cells, invasion assays

    PMID:18283340

    Open questions at the time
    • Direct chromatin targets not yet defined
    • Cooperating lesions for full transformation unclear
  8. 2011 High

    Multiple studies established ERG as a broad hematopoietic oncogene, driving megakaryopoiesis, cooperating with GATA1s, and supporting multi-lineage leukemias.

    Evidence Retroviral overexpression/shRNA in mouse BM transplants and human leukemia lines, serial replating, JAK/STAT analysis

    PMID:19168790 PMID:19487285 PMID:21321361

    Open questions at the time
    • Direct transcriptional targets in each lineage incompletely defined
    • Mechanism of GATA1s cooperation at chromatin unresolved
  9. 2013 High

    Solving ERG crystal structures with NMR dynamics answered how DNA binding is regulated, showing autoinhibition operates by quenching Ets-domain dynamics rather than gross conformational change.

    Evidence Three X-ray structures, NMR backbone dynamics, DNA-binding assays

    PMID:23898196

    Open questions at the time
    • How post-translational modifications alter these dynamics not addressed here
    • Partner-protein influence on autoinhibition unknown
  10. 2013 High

    Mapping ERG-regulated targets in prostate cancer (SOX9, TFF3, PIM1, TDRD1, ANXA2) revealed both direct ETS-site binding and AR-redirection, establishing the effector genes for invasion and EMT.

    Evidence ChIP/ChIP-seq, MeDIP-seq, knockdown/overexpression, xenografts, clinical cohorts

    PMID:21170267 PMID:22140532 PMID:23426182 PMID:23555854 PMID:25344575

    Open questions at the time
    • Relative contribution of each target to tumorigenesis unranked
    • Direct vs. AR-mediated mechanism varies by target
  11. 2014 Medium

    Identifying a non-nuclear ERG effect on microtubule dynamics proposed a mechanism for taxane resistance distinct from its transcriptional role.

    Evidence Overexpression, microtubule and drug-target engagement assays, clinical cohort

    PMID:25420520

    Open questions at the time
    • Direct ERG-tubulin interaction not biochemically defined
    • Single lab, mechanism of cytoplasmic localization unclear
  12. 2014 Medium

    Demonstrating ERG-Smad3 interaction and TGF-β induction of ERG connected ERG to TGF-β signaling in skeletal differentiation.

    Evidence Micromass culture, Co-IP, TGF-β bead implantation in chick, marker analysis

    PMID:25139621

    Open questions at the time
    • Co-IP not reciprocally validated for endogenous proteins
    • Direct target genes of ERG-Smad3 complex undefined
  13. 2015 High

    Identifying SPOP/CRL3 as the E3 ligase recognizing an N-terminal ERG degron answered how ERG protein is degraded and why truncated fusions escape turnover.

    Evidence Ubiquitination assays, degron mapping, SPOP-mutant and CKI/DNA-damage modulation, in vivo

    PMID:26344095 PMID:26344096

    Open questions at the time
    • Interplay with other degradation pathways not yet integrated
    • CKI site on ERG not precisely mapped here
  14. 2015 High

    Establishing the ERG-YAP1/Hippo axis (with KDM4A cooperation) revealed a transcriptional program shared with YAP1 that drives prostate tumorigenesis.

    Evidence ChIP-seq, promoter ChIP/luciferase, Co-IP, mouse genetic models

    PMID:26058078 PMID:27109047

    Open questions at the time
    • Whether YAP1 fully accounts for ERG tumor phenotype unresolved
    • KDM4A-ERG interaction from single lab
  15. 2016 High

    Defining ERG's recruitment of BAF remodelers and interaction with BRD4 answered how fusion ERG reorganizes chromatin to reprogram lineage identity.

    Evidence Co-IP/binding, ChIP-seq, BAF ATPase inhibition, organoids, BET inhibitor and acetylation-mimic experiments

    PMID:27223260 PMID:30078722

    Open questions at the time
    • Stoichiometry and direct interface of ERG-BAF binding undefined
    • BRD4 interaction characterized in single lab
  16. 2016 High

    Discovering EndMT control by ERG/FLI1 and ERGalt dominant-negative isoform expanded ERG's roles to endothelial identity maintenance and a novel B-ALL transforming mechanism.

    Evidence siRNA knockdown, ChIP-seq/ATAC-seq, miR-126 rescue, RNA-seq, transactivation/transformation assays

    PMID:27776115 PMID:30500808

    Open questions at the time
    • Generality of ERGalt across B-ALL subtypes incompletely defined
    • Tumor-microenvironment factors downregulating ERG unidentified
  17. 2017 High

    ERG inhibitory peptides binding the DNA-binding domain established druggability and confirmed that disrupting ERG-DNA/protein interactions degrades ERG and blocks tumor growth.

    Evidence Peptide binding, protease degradation assay, ChIP, reporter and invasion assays, xenografts

    PMID:28344039

    Open questions at the time
    • Degradation mechanism downstream of peptide binding not fully detailed
    • Clinical translation untested
  18. 2017 High

    Identifying FOXO1 as a direct ERG-binding inhibitor revealed an endogenous brake on ERG transcriptional activity that cooperates genetically in PIN.

    Evidence Co-IP, reporter assays, knockdown, mouse ERG transgene + Foxo1 deletion, invasion

    PMID:28986382

    Open questions at the time
    • Structural basis of FOXO1-ERG inhibition undefined
    • Whether FOXO1 affects ERG at all target loci unknown
  19. 2019 High

    Linking ERG to direct activation of sGC α1/β1 subunits revealed a cGMP/PKG proliferative pathway and a druggable vulnerability synergizing with enzalutamide.

    Evidence ChIP, knockdown/overexpression, cGMP/PKG assays, xenografts, pharmacological inhibition

    PMID:30718921

    Open questions at the time
    • Whether sGC axis operates in non-prostate ERG contexts untested
    • Upstream signals converging on this pathway unclear
  20. 2020 High

    Three studies clarified how fusion ERG maintains AR signaling and lineage identity: it sustains AR coregulators/Pol II rather than AR binding, and enforces luminal identity by silencing a Trp63 enhancer through 3D looping; ERG also governs B-lineage transcription.

    Evidence Organoid ERG deletion, AR/H3K27ac ChIP-seq, ATAC-seq, proteomics, Hi-C, CRISPR enhancer deletion, conditional KO, Ig rescue

    PMID:32541654 PMID:32701507 PMID:32934023

    Open questions at the time
    • Mechanism by which ERG retains NCOA3/Pol II at AR sites undefined
    • Generalizability of looping mechanism to other ERG targets unknown
  21. 2020 High

    Defining GSK3β/WEE1 dual phosphorylation (T187/Y190) recruiting FBW7 revealed a degron-independent, DNA-damage-inducible route to ERG degradation gated by PTEN status.

    Evidence Kinase and ubiquitination assays, mutagenesis, FBW7 Co-IP, PTEN deletion, xenograft chemotherapy

    PMID:32871104

    Open questions at the time
    • Crosstalk with SPOP/CKI degron pathway not fully integrated
    • Whether this operates in non-prostate ERG tumors untested
  22. 2021 High

    EZH2 methylation of ERG-K362 and the ERG-SPOP-ZMYND11 feedback loop answered how ERG activity and stability are reciprocally tuned, linking PTEN/AKT signaling and SPOP-mutation status to ERG function.

    Evidence In vitro methylation, mutagenesis, Co-IP, ChIP-seq, ERG/PTEN mouse model, ZMYND11 stability and clinical analyses

    PMID:33531470 PMID:34230470

    Open questions at the time
    • Quantitative impact of K362 methylation on genome-wide binding incompletely mapped
    • Therapeutic exploitation of SPOP-ERG synthetic-sick interaction unproven clinically
  23. 2022 High

    Establishing ERG as the direct EVI1 transcriptional effector and the HNF1B partnership clarified ERG's place in AML dependency and prostate cancer risk-locus biology.

    Evidence EVI1 withdrawal, CRISPR screens, ChIP-seq, shRNA/ectopic rescue, eQTL stratified by ERG status

    PMID:36095844 PMID:36443337

    Open questions at the time
    • HNF1B finding predominantly genomic, single study
    • Direct ERG-HNF1B physical interaction not biochemically confirmed
  24. 2022 High

    Endothelial ERG was shown to govern fibrosis resolution and aging-associated chromatin accessibility, extending its homeostatic role to tissue repair.

    Evidence Conditional endothelial KO, bleomycin model, ATAC-seq, scRNA-seq, paracrine assays

    PMID:35879310

    Open questions at the time
    • Direct ERG targets driving fibrosis resolution not pinpointed
    • Mechanism of age-related ERG dysregulation unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the multiple ERG-regulatory layers — autoinhibition, K362 methylation, dual degron/phosphodegron degradation pathways, and partner complexes — are integrated to set context-specific ERG output across endothelium, hematopoiesis, and tumors remains unresolved.
  • No unified model coordinating ERG PTMs, stability, and chromatin partners
  • Determinants of cell-type-specific target selection undefined
  • Translation of ERG-targeting strategies to clinic untested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 8 GO:0003677 DNA binding 3 GO:0140098 catalytic activity, acting on RNA 2
Localization
GO:0005634 nucleus 4
Pathway
R-HSA-74160 Gene expression (Transcription) 6 R-HSA-1643685 Disease 4 R-HSA-4839726 Chromatin organization 4 R-HSA-392499 Metabolism of proteins 3
Partners
ARBRD4EZH2FBW7FOXO1KDM4ASMAD3SPOP
Complex memberships
BAF (mammalian SWI/SNF)

Evidence

Reading pass · 40 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1987 ERG (erg gene) encodes a protein with ~40% and ~70% homology to the 5' and 3' domains of v-ets oncogene, respectively, establishing it as a member of the ETS oncogene family with a distinct transcript size from Hu-ets1 and Hu-ets2. cDNA cloning, nucleotide sequence analysis, Northern blot Proceedings of the National Academy of Sciences of the United States of America High 3476934
1991 ERG-1 and ERG-2 proteins (produced by alternative splicing and alternative initiation codons) bind DNA in a sequence-specific manner and transactivate reporter genes linked to ERG target sequences, establishing ERG as a sequence-specific transcriptional activator with partially overlapping but distinct DNA-binding specificity compared to other ETS members. Recombinant protein expression in E. coli, DNA-binding assays, transactivation reporter assays in transient transfection Oncogene High 1766675
1994 ERG gene on chromosome 21 is fused to the 5' end of EWS in Ewing's sarcoma, placing the ERG ETS DNA-binding domain adjacent to the EWS CTD-related region and generating an elevated EWS/ERG fusion transcript — the first reported structural alteration of ERG in human cancer. Cytogenetics, RT-PCR, transcript detection in cell line Cancer genetics and cytogenetics Medium 8076344
2000 The TLS-ERG leukemia fusion protein binds RNA polymerase II through its TLS N-terminal domain but, unlike wild-type TLS, cannot recruit serine-arginine (SR) splicing factors because the ERG portion replaces the TLS C-terminal SR-recruiting domain; as a result, TLS-ERG inhibits SR-mediated E1A pre-mRNA splicing and alters CD44 mRNA splicing in stable K562 cells. Co-immunoprecipitation, transient transfection splicing assay, stable expression in K562 cells, RT-PCR of CD44 splice variants, deletion analysis Molecular and cellular biology High 10779324
2001 Among multiple ERG isoforms, Erg-3/p55(ERG) and p38(ERG)-like transcripts are selectively expressed in human endothelial cells (both microvascular and large vessel), suggesting isoform-specific roles in regulating endothelial-restricted genes. RT-PCR, Northern blotting, 5'-RACE on primary and established human endothelial cells The international journal of biochemistry & cell biology Medium 11312105
2005 TLS-ERG binds RNA polymerase II via its first 173 amino acids; in myeloid L-G cells TLS-ERG represses glycoprotein IX promoter activity, while in NIH 3T3 fibroblasts it alters E1A splicing but not GpIX transcription — demonstrating cell-type-specific mechanisms of transformation through different gene sets. Deletion mutant analysis, luciferase reporter assays, splicing reporter assay, stable retroviral expression, microarray gene expression profiling in two cell lines Molecular and cellular biology High 15988032
2007 ERG and its splice variant C-1-1 (hERG3Δ81) are expressed in developing mouse limb joints and overexpression of hERG3Δ81 throughout the cartilaginous skeleton of transgenic mice inhibits chondrocyte maturation/hypertrophy (absent growth plates, loss of Indian hedgehog, collagen X, MMP-13) while maintaining articular markers, placing ERG downstream of GDF-5 in joint formation. In vivo transgenic mouse model (Col2a1-driven overexpression), GDF-5 bead implantation in explants, immunostaining and marker expression analysis Developmental biology High 17336282
2008 ERG binds the VE-cadherin promoter (shown by ChIP) and transactivates it; inhibition of ERG in HUVECs reduces VE-cadherin expression, disrupts cell-cell contacts, and increases apoptosis; overexpression of VE-cadherin rescues ERG-knockdown-induced apoptosis; in vivo ERG siRNA reduces Matrigel plug vascularization with increased caspase-positive ECs. Antisense oligonucleotide knockdown, siRNA, chromatin immunoprecipitation (ChIP), transactivation assay, VE-cadherin-GFP overexpression rescue, in vivo Matrigel plug model, caspase staining Blood High 18195090
2008 TMPRSS2-ERG fusion product induces an invasion-associated transcriptional program in prostate epithelial cells and directly engages the plasminogen activation pathway to mediate cellular invasion; transgenic mice expressing ERG under androgen regulation develop prostatic intraepithelial neoplasia. Transgenic mouse model, stable overexpression in primary/immortalized prostate cells, ERG knockdown in VCaP cells, transcriptional profiling, invasion assays Neoplasia High 18283340
2009 Ectopic ERG expression in fetal hematopoietic progenitors promotes megakaryopoiesis and causes rapid-onset leukemia in mice; ERG cooperates strongly with the GATA1s mutant protein to immortalize megakaryocyte progenitors, and endogenous ERG is required for proliferation/maintenance of AMKL cell lines. Retroviral overexpression in fetal liver progenitors, in vivo mouse transplantation, shRNA knockdown of ERG in human AMKL lines, colony-forming assays Cancer research High 19487285
2009 ETS2 and ERG overexpression immortalize Gata1-knockdown and Gata1s-knockin (but not wild-type) murine fetal liver megakaryocyte progenitors in serial replating; immortalization is accompanied by activation of the JAK/STAT pathway. Retroviral overexpression in Gata1 mutant fetal liver progenitors, serial replating assay, flow cytometry (CD41/CD42), JAK/STAT signaling analysis Blood High 19168790
2011 ERG forced expression in adult bone marrow cells promotes T-cell and erythroid expansion and increases myeloid progenitor frequency; T cells develop T-ALL after acquiring Notch1 mutations; ERG targeted to B cells promotes precursor-B-cell growth; shRNA silencing of ERG attenuates growth of human leukemia lines of multiple lineages. Retroviral overexpression and shRNA knockdown in mouse BM transplantation models; B-cell targeted expression; human leukemia cell line knockdown Blood High 21321361
2011 TMPRSS2-ERG directly binds the TFF3 promoter ETS sites (by ChIP and ChIP-seq), inhibiting TFF3 expression in hormone-naive cancer but not in castration-resistant prostate cancer; AR signaling modulates ERG-regulated TFF3 expression; TFF3 overexpression enhances ERG-mediated invasion in CRPC cells. ChIP-PCR and ChIP-seq in VCaP cells and tissue specimens, transcriptome profiling of 54 CRPC samples, invasion assays with TFF3 overexpression Neoplasia High 21170267
2011 ERG directly binds the PIM1 promoter (by ChIP) in prostate cells and upregulates PIM1 expression; all three ERG oncogenic fusions (TMPRSS2/ERG, EWS/ERG, FUS/ERG) upregulate PIM1 in NIH-3T3; tERG-induced PIM1 upregulation increases Cyclin B1 levels and aneuploidy after taxane treatment. Chromatin immunoprecipitation, stable expression of ERG fusions in NIH-3T3 and RWPE-1, siRNA knockdown, gene expression microarray, flow cytometry PloS one Medium 22140532
2013 ERG-mediated regulation of SOX9 is indirect: ERG redirects AR to a cryptic AR-regulated enhancer in the SOX9 gene, thereby driving androgen-stimulated SOX9 expression; SOX9 depletion in VCaP cells impairs invasion and growth in vitro and in vivo, establishing SOX9 as a critical downstream effector of ERG. RNAi knockdown in VCaP cells, ChIP-seq to map ERG/AR binding at SOX9 enhancer, SOX9 shRNA knockdown, in vivo xenograft, correlation in 3 independent cohorts The Journal of clinical investigation High 23426182
2013 ERG DNA binding is allosterically autoinhibited by flanking regions outside the ETS domain. Crystal structures of uninhibited, autoinhibited, and DNA-bound ERG were solved; NMR backbone dynamics show that uninhibited ERG exhibits millisecond-to-microsecond dynamics that are quenched in autoinhibited and DNA-bound states, revealing that autoinhibition is predominantly mediated by regulation of Ets-domain dynamics rather than large structural changes. X-ray crystallography (three crystal structures), NMR backbone dynamics measurements, functional DNA-binding assays Proceedings of the National Academy of Sciences of the United States of America High 23898196
2013 ERG governs loss of DNA methylation at the TDRD1 promoter CpG island, leading to TDRD1 transcriptional activation in TMPRSS2:ERG-positive prostate cancer; this was demonstrated by ERG dosage manipulation (siRNA and forced expression) and MeDIP-seq/bisulfite sequencing showing inverse correlation between ERG and TDRD1 promoter methylation. siRNA knockdown and forced expression of ERG, MeDIP-Seq and bisulfite sequencing, DNMT inhibitor treatment, quantitative RT-PCR, clinical specimen analysis PloS one Medium 23555854
2013 ERG is recruited to the ANXA2 promoter (shown by ChIP) and transcriptionally represses ANXA2; ERG knockdown enhances apical ANXA2 localization and promotes polarized epithelial phenotype; ERG overexpression disrupts ANXA2-mediated cell polarity and promotes EMT by inhibiting CDC42 and RHOA and activating cofilin. ChIP, siRNA knockdown, ERG overexpression, immunofluorescence of ANXA2 localization, RHOA/CDC42/cofilin activity assays, IHC in clinical specimens Molecular cancer research High 25344575
2014 ERG overexpression in CRPC cells affects microtubule dynamics and inhibits effective drug-target engagement of docetaxel or cabazitaxel with tubulin, suggesting ERG functions outside the nucleus to confer taxane resistance. ERG overexpression in in vitro and in vivo CRPC models, microtubule dynamics assays, drug-target engagement assays, clinical cohort analysis (34 patients) Nature communications Medium 25420520
2014 ERG cooperates with TGF-β signaling: ERG expression is induced by TGF-β in sclerotome cells; Erg and Smad3 co-immunoprecipitate, indicating direct protein-protein interaction; ERG overexpression inhibits hyaline cartilage differentiation (reduced Alcian blue, Sox9, c-Maf) and upregulates Sca1; TGF-β enhances ERG-mediated differentiation marker expression. Micromass culture, adenoviral ERG overexpression, co-immunoprecipitation (Erg/Smad3), TGF-β bead implantation in chick embryo, Alcian blue staining, qRT-PCR Experimental cell research Medium 25139621
2015 SPOP (Cullin 3-based E3 ubiquitin ligase adaptor) promotes ubiquitination and proteasomal degradation of ERG by recognizing a degron motif at the ERG N-terminus; truncated TMPRSS2-ERG fusion proteins lacking the N-terminal degron are resistant to SPOP-mediated degradation; prostate cancer-associated SPOP mutants are deficient in promoting ERG ubiquitination; CKI-mediated phosphorylation modulates the SPOP/ERG interaction; DNA damage drugs can restore SPOP/ΔERG interaction and degradation via CKI activation. Ubiquitination assay, co-immunoprecipitation, proteasome inhibitor treatment, SPOP mutant expression, CKI activation by DNA damage drugs, in vitro and in vivo experiments Molecular cell High 26344095 26344096
2015 ERG activates the YAP1 transcriptional program: ERG binds chromatin regions co-occupied by TEAD/YAP1 and transactivates Hippo target genes; in human luminal prostate cancer cells, ERG binds the YAP1 promoter and is necessary for YAP1 expression; prostate-specific activation of ERG or YAP1 in mice induces similar transcriptional changes and age-related prostate tumors. ChIP-seq (ERG/TEAD/YAP1 binding), ERG and YAP1 promoter ChIP, mouse genetic models (prostate-specific ERG or YAP1 activation), transcriptional profiling Cancer cell High 26058078
2015 ERG directly promotes YAP1 expression by binding to multiple sites within the human YAP1 gene promoter, cooperating with histone demethylase KDM4A (JMJD2A) which removes H3K9me3 at the YAP1 promoter; ERG and KDM4A physically interact (co-IP); YAP1 depletion phenocopies ERG or KDM4A depletion in VCaP cells. Co-immunoprecipitation (ERG-KDM4A), ChIP (H3K9me3 at YAP1 promoter), luciferase promoter assays with ERG-binding-site mutations, siRNA knockdown, growth assays Oncology reports Medium 27109047
2016 ERG drives genome-wide retargeting of BAF (mammalian SWI/SNF) ATP-dependent chromatin remodeling complexes in a manner dependent on ERG binding to ETS DNA motifs; ERG requires intact BAF complexes for chromatin occupancy and BAF ATPase activity for target gene regulation; ERG interacts with BAF complexes (shown by binding interaction experiments); BAF complexes are required for ERG-mediated basal-to-luminal transition in prostate organoids. Co-immunoprecipitation/binding interaction experiments, ChIP-seq (ERG and BAF), BAF ATPase inhibition, prostate organoid model with BAF complex perturbation Molecular cell High 30078722
2016 Combined knockdown of ERG and FLI1 in endothelial cells induces EndMT coupled with dynamic epigenetic changes; ERG (and FLI1) are critical transcriptional activators of EC-specific genes; microRNA-126, a target of ERG/FLI1, partially contributes to blocking EndMT; ERG and FLI1 expression is downregulated in ECs within tumors by soluble factors from the tumor microenvironment. siRNA knockdown (ERG, FLI1, combined), genome-wide ChIP-seq and ATAC-seq, EndMT phenotyping, miR-126 rescue experiments, conditioned medium experiments PLoS genetics High 30500808
2016 The TMPRSS2-ERG truncated fusion protein (ERGΔ39/T1-E4) binds bromodomain-1 (BD1) of BRD4; this interaction is partially abrogated by BET inhibitors JQ1 and iBET762; ChIP-seq shows substantial overlap of ERG and BRD4 binding sites; an acetylation-mimicking ERG mutation augments the ERG-BRD4 interaction and enhances ERG-mediated invasion. Co-immunoprecipitation (ERG-BRD4), BET inhibitor treatment, ChIP-seq meta-analysis, acetylation-mimicking mutation, invasion assays Oncotarget Medium 27223260
2016 Deregulation of DUX4 in B-progenitor ALL initiates transcription of a novel ERG isoform (ERGalt) from a non-canonical first exon via DUX4 binding; ERGalt retains the DNA-binding and transactivation domains of ERG but acts as a dominant-negative inhibitor of wild-type ERG transcriptional activity and is transforming. RNA-seq, genomic rearrangement analysis, functional transactivation assays (dominant-negative), transformation assays, DUX4 binding site characterization Nature genetics High 27776115
2017 Peptides and derived peptidomimetics (ERG inhibitory peptides, EIPs) interact specifically with the DNA-binding domain of ERG; binding leads to proteolytic degradation of ERG protein; EIPs attenuate ERG-mediated transcription, chromatin recruitment, protein-protein interactions, cell invasion and proliferation, and tumor growth in vivo. Peptide binding assays, protease degradation assay, ERG ChIP after EIP treatment, transcriptional reporter assays, invasion/proliferation assays, xenograft tumor model Cancer cell High 28344039
2017 FOXO1 (but not FOXO3 or FOXO4) directly binds ERG and inhibits its transcriptional activity independently of FOXO1's own transcriptional activity; FOXO1 knockdown increases invasion of VCaP cells in an ERG-dependent manner; combined ERG overexpression and homozygous Foxo1 deletion in mouse prostate cooperates to produce high-grade PIN, while either alone does not. Co-immunoprecipitation (FOXO1-ERG), transcriptional reporter assay, siRNA knockdown, mouse genetic model (ERG transgene + Foxo1 deletion), cell invasion assay Cancer research High 28986382
2019 ERG directly and specifically regulates expression of the α1 and β1 subunits of soluble guanylyl cyclase (sGC) in prostate cancer cells; ERG-driven sGC expression increases cGMP synthesis and PKG activity, promoting cell proliferation; sGC inhibitor treatment represses TMPRSS2-ERG-positive tumor growth in xenograft models and synergizes with enzalutamide. ERG knockdown/overexpression in PCa cells, ChIP (ERG at sGC subunit loci), cGMP measurement, PKG activity assay, xenograft tumor model, pharmacological inhibition Oncogene High 30718921
2020 DNA damage induces proteasomal degradation of ERG and TMPRSS2-ERG oncoprotein through dual phosphorylation at threonine-187 (by GSK3β) and tyrosine-190 (by WEE1); this dual phosphorylation triggers recognition and degradation by the E3 ubiquitin ligase FBW7 independent of a canonical degron; DNA-damage-induced TMPRSS2-ERG degradation is abolished by PTEN deletion or GSK3β inactivation. In vitro phosphorylation assays, ubiquitination assays, mutagenesis (T187 and Y190), FBW7 Co-IP and degradation assays, GSK3β/WEE1 inhibition, PTEN deletion models, xenograft chemotherapy experiments Molecular cell High 32871104
2020 ERG initiates a transcriptional network in early B lymphoid differentiation, directly promoting expression of B-cell lineage-defining genes Ebf1 and Pax5, which in turn regulate key genes for V(D)J recombination and B-cell receptor formation; ERG deficiency in B-cell development is rescued by a productively rearranged immunoglobulin gene, placing ERG as an essential stage-specific regulator upstream of V(D)J recombination. Erg conditional knockout, transcriptional profiling, ChIP-seq, Ig gene rescue complementation experiment, flow cytometric characterization of B-cell progenitor stages Nature communications High 32541654
2020 ERG orchestrates 3D chromatin interactions in prostate cancer to enforce luminal cell identity: ERG binds and inhibits the enhancer activity and chromatin looping of a Trp63 distal enhancer, silencing Trp63 expression and suppressing basal lineage differentiation; specific deletion of the ERG-bound distal enhancer element abolishes ERG-mediated inhibition of basal differentiation. Integration of transcription factor analysis across 806 human PCa transcriptomes, 3D chromatin architecture analysis (Hi-C/chromatin conformation), ChIP-seq, CRISPR enhancer deletion, ERG/AR conditional KO in organoids The Journal of clinical investigation High 32701507
2020 In established prostate cancer organoids, ERG deletion does not drastically alter AR binding, H3K27ac enhancer, or open chromatin profiles at ERG-reprogrammed sites, but does cause loss of critical AR coregulators (NCOA3) and RNA polymerase II from AR-bound sites, revealing that ERG maintains AR signaling by sustaining coregulator complexes rather than by controlling AR binding. Murine prostate organoids (Pten KO + ERG OE), ERG deletion in established organoids, ChIP-seq (AR, H3K27ac), ATAC-seq, proteomic analysis of DNA-bound AR complexes Cancer research High 32934023
2021 EZH2 methylates ERG at lysine K362 within the internal autoinhibitory domain; K362 methylation modifies intradomain interactions, favors DNA binding, and enhances ERG transcriptional activity; in PTEN-null prostate cancer, AKT activation leads to EZH2 phosphorylation at serine 21, promoting ERG methylation; ERG and EZH2 physically interact and co-occupy genomic sites forming trans-activating complexes. In vitro methylation assay, site-directed mutagenesis (K362), Co-IP (ERG-EZH2), ChIP-seq, genetically engineered mouse model (ERG/PTEN), AKT/EZH2 signaling dissection Nature communications High 34230470
2021 ERG upregulates wild-type SPOP to dampen AR signaling and sustains its own activity through SPOP-mediated degradation of the bromodomain histone reader ZMYND11; conversely, SPOP-mutant tumors stabilize ZMYND11 which represses ERG function, creating a synthetic-sick interaction between ERG and SPOP mutation; ERG promotes sensitivity to high-dose androgen therapy and pharmacological SPOP inhibition. ERG/SPOP gain and loss of function, ZMYND11 protein stability assays, AR signaling readouts, pharmacological inhibition, clinical cohort analysis Nature communications High 33531470
2021 ERG knockdown in endothelial cells (HUVECs) promotes secretion of endothelin-1 (ET-1), which in a paracrine manner accelerates proliferation, phenotypic transition, and collagen synthesis of cardiac fibroblasts; suppressing ET-1 (neutralizing antibody or receptor blocker) abolishes ERG-knockdown-mediated pro-fibrotic effects; endothelial ERG overexpression prevents pressure-overload-induced cardiac fibrosis in vivo. siRNA knockdown of ERG in HUVECs, ET-1 ELISA, cardiac fibroblast co-culture/conditioned medium, ET-1 neutralizing antibody/receptor blocker, RGD-peptide nanoparticle siRNA delivery in vivo, pressure-overload mouse model with ERG overexpression Cell biology and toxicology High 33469864
2022 EVI1 oncogene directly transcriptionally activates ERG by occupying a conserved intragenic enhancer region; ERG is a direct transcriptional target of EVI1 and is selectively required in EVI1-driven AML; ERG suppression induces terminal differentiation of EVI1-driven AML cells; ectopic ERG expression abrogates EVI1 dependence, placing ERG downstream of EVI1 as the major oncogenic effector. EVI1 withdrawal experiments, genome-wide CRISPR screens for dependencies, ChIP-seq (EVI1 at ERG enhancer), ERG shRNA knockdown, ERG ectopic expression rescue, differentiation assays in human and murine AML models Blood High 36095844
2022 Loss of endothelial ERG in young mice impairs lung fibrosis resolution; ERG dysregulation in aged lungs is associated with reduced chromatin accessibility at ERG target loci and maladaptive transcriptional responses to injury; ERG deficiency enhances paracrine fibroblast activation in vitro; scRNA-seq of ERG-deficient mouse lungs shows transcriptional and fibrogenic abnormalities resembling aging, including reduced general capillary (gCap) ECs. Conditional endothelial ERG KO, bleomycin fibrosis model, ATAC-seq (epigenetic chromatin accessibility), scRNA-seq, in vitro paracrine fibroblast activation assay, young vs. aged mouse comparison Nature communications High 35879310
2022 HNF1B interacts with TMPRSS2-ERG to co-occupy large genomic regions enriched for PCa risk alleles; the HNF1B eQTL signal is ERG fusion-status dependent, indicating that ERG mediates the transcriptional effects of the 17q12/HNF1B risk locus; HNF1B co-opts ERG fusion to mediate the biological effects of the 17p13.3 PCa risk locus. Co-expression analysis, eQTL analysis stratified by ERG status, ChIP-seq co-occupancy analysis, functional pathway analysis Nature communications Medium 36443337

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2008 Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (New York, N.Y.) 565 18283340
2012 The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 271 22736790
2016 Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nature genetics 251 27776115
2013 ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. The Journal of clinical investigation 230 23426182
2008 Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood 227 18195090
2015 The oncogene ERG: a key factor in prostate cancer. Oncogene 211 25915839
2006 TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia (New York, N.Y.) 197 17032499
1987 The erg gene: a human gene related to the ets oncogene. Proceedings of the National Academy of Sciences of the United States of America 188 3476934
2015 SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. Molecular cell 181 26344095
2011 ERG gene rearrangements are common in prostatic small cell carcinomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 169 21336263
2015 A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. Journal of the National Cancer Institute 157 26615022
2015 Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. Molecular cell 136 26344096
2011 Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. The American journal of surgical pathology 130 21677539
2010 Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 130 20118910
2016 Regulation of endothelial homeostasis, vascular development and angiogenesis by the transcription factor ERG. Vascular pharmacology 120 27208692
2015 Ewing sarcoma with ERG gene rearrangements: A molecular study focusing on the prevalence of FUS-ERG and common pitfalls in detecting EWSR1-ERG fusions by FISH. Genes, chromosomes & cancer 114 26690869
2015 ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors. Cancer cell 113 26058078
2000 TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins. Molecular and cellular biology 113 10779324
2021 Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 106 34397171
2009 ERG is a megakaryocytic oncogene. Cancer research 102 19487285
2014 TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers. PloS one 100 24505269
2005 The proto-oncogene ERG in megakaryoblastic leukemias. Cancer research 98 16140924
2014 ERG induces taxane resistance in castration-resistant prostate cancer. Nature communications 97 25420520
2012 Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 97 22766791
2009 ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells. Blood 97 19168790
1993 The effects of dystrophin gene mutations on the ERG in mice and humans. Investigative ophthalmology & visual science 93 8258524
2000 Multifocal ERG and VEP responses and visual fields: comparing disease-related changes. Documenta ophthalmologica. Advances in ophthalmology 91 11142742
2018 Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis. Molecular cell 89 30078722
2007 Transcription factor ERG and joint and articular cartilage formation during mouse limb and spine skeletogenesis. Developmental biology 87 17336282
2017 Significance of the TMPRSS2:ERG gene fusion in prostate cancer. Molecular medicine reports 85 28849022
2011 YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. PloS one 85 21559405
2013 ERG expression in epithelioid sarcoma: a diagnostic pitfall. The American journal of surgical pathology 82 23774169
2021 Endothelial ERG alleviates cardiac fibrosis via blocking endothelin-1-dependent paracrine mechanism. Cell biology and toxicology 75 33469864
1991 erg, an ets-related gene, codes for sequence-specific transcriptional activators. Oncogene 75 1766675
2022 Dysfunctional ERG signaling drives pulmonary vascular aging and persistent fibrosis. Nature communications 74 35879310
2011 Promotion and maintenance of leukemia by ERG. Blood 72 21321361
2017 Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. Cancer cell 69 28344039
2014 Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 63 24762546
2018 Downregulation of ERG and FLI1 expression in endothelial cells triggers endothelial-to-mesenchymal transition. PLoS genetics 62 30500808
2004 Functions of erg K+ channels in excitable cells. Journal of cellular and molecular medicine 60 15090257
1994 ERG gene is translocated in an Ewing's sarcoma cell line. Cancer genetics and cytogenetics 59 8076344
2017 Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion. Cancer research 55 28986382
2014 TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation. Oncogene 52 25263440
2012 Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. American journal of clinical pathology 52 23086769
2010 ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia (New York, N.Y.) 51 21170267
2010 ERG rearrangement in small cell prostatic and lung cancer. Histopathology 49 20636794
2013 Structural and dynamic studies of the transcription factor ERG reveal DNA binding is allosterically autoinhibited. Proceedings of the National Academy of Sciences of the United States of America 47 23898196
2016 BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion. Oncotarget 44 27223260
2009 TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 44 19151660
2020 An Erg-driven transcriptional program controls B cell lymphopoiesis. Nature communications 43 32541654
2020 ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming. The Journal of clinical investigation 42 32701507
2021 Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer. Nature communications 41 33531470
2019 ISCEV extended protocol for the S-cone ERG. Documenta ophthalmologica. Advances in ophthalmology 41 31749034
2020 DNA Damage Promotes TMPRSS2-ERG Oncoprotein Destruction and Prostate Cancer Suppression via Signaling Converged by GSK3β and WEE1. Molecular cell 39 32871104
2017 TMPRSS2-ERG fusion promotes prostate cancer metastases in bone. Oncotarget 38 28055969
2017 Synergistic Role of Endothelial ERG and FLI1 in Mediating Pulmonary Vascular Homeostasis. American journal of respiratory cell and molecular biology 38 28248553
2014 ERG expression in chondrogenic bone and soft tissue tumours. Journal of clinical pathology 38 25378537
2021 EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer. Nature communications 37 34230470
2007 ERG upregulation and related ETS transcription factors in prostate cancer. International journal of oncology 37 17143509
2023 EVI1 drives leukemogenesis through aberrant ERG activation. Blood 36 36095844
2016 ETS transcription factor ERG cooperates with histone demethylase KDM4A. Oncology reports 35 27109047
2001 Selective expression of erg isoforms in human endothelial cells. The international journal of biochemistry & cell biology 34 11312105
2018 Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers. European urology oncology 33 29911685
2019 TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells. Oncogene 32 30718921
2022 The Expression of Proto-Oncogene ETS-Related Gene (ERG) Plays a Central Role in the Oncogenic Mechanism Involved in the Development and Progression of Prostate Cancer. International journal of molecular sciences 31 35563163
2014 ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells. Oncotarget 31 24504051
2016 PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 30 27041928
2017 SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. The Journal of clinical investigation 28 29202479
2011 ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells. PloS one 26 22140532
2013 5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer. PloS one 25 23472063
2013 ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer. PloS one 24 23555854
2015 Elevated expression of microRNA-30b in osteoarthritis and its role in ERG regulation of chondrocyte. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 23 26653555
2011 ERG oncogene modulates prostaglandin signaling in prostate cancer cells. Cancer biology & therapy 23 21178489
2011 Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression. PloS one 23 21731703
2018 Wnt receptor Frizzled 8 is a target of ERG in prostate cancer. The Prostate 22 30051493
2015 Expression of ERG protein in prostate cancer: variability and biological correlates. Endocrine-related cancer 22 25972242
2013 AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL. Leukemia 21 23380710
2022 Extensive germline-somatic interplay contributes to prostate cancer progression through HNF1B co-option of TMPRSS2-ERG. Nature communications 20 36443337
2017 Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20 29167279
2013 Immunohistochemical evaluation of ERG expression in various benign and malignant tissues. Annals of clinical and laboratory science 20 23462600
2010 The oncogenic role of the ETS transcription factors MEF and ERG. Cell cycle (Georgetown, Tex.) 20 20814243
2019 ERG the modulates Warburg effect and tumor progression in cervical cancer. Biochemical and biophysical research communications 19 31757416
2017 Reduced Erg Dosage Impairs Survival of Hematopoietic Stem and Progenitor Cells. Stem cells (Dayton, Ohio) 19 28436588
2015 Endothelial Erg expression is required for embryogenesis and vascular integrity. Organogenesis 19 26061019
2020 High Specificity of BCL11B and GLG1 for EWSR1-FLI1 and EWSR1-ERG Positive Ewing Sarcoma. Cancers 18 32164354
2013 ERG expression and prostatic adenocarcinoma. Virchows Archiv : an international journal of pathology 18 23703293
2022 Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer. Cell & bioscience 17 36088396
2021 LncRNA SNHG3 Facilitates the Malignant Phenotype of Cholangiocarcinoma Cells via the miR-3173-5p/ERG Axis. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 17 34647226
2018 Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer. Scientific reports 17 30150711
2014 Erg cooperates with TGF-β to control mesenchymal differentiation. Experimental cell research 17 25139621
2023 PCA3 and TMPRSS2: ERG Urine Level as Diagnostic Biomarker of Prostate Cancer. Research and reports in urology 16 37181497
2022 Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer. BMC cancer 16 35513774
2018 Molecular characteristic of acute leukemias with t(16;21)/FUS-ERG. Annals of hematology 16 29427188
2017 Clinical Utility and Biologic Implications of Phosphatase and Tensin Homolog (PTEN) and ETS-related Gene (ERG) in Prostate Cancer. Urology 16 29225123
2015 ERG and FLI1 are useful immunohistochemical markers in phosphaturic mesenchymal tumors. Medical molecular morphology 16 26122367
2005 The oncogenic TLS-ERG fusion protein exerts different effects in hematopoietic cells and fibroblasts. Molecular and cellular biology 16 15988032
2021 Periodontitis Risk Variants at SIGLEC5 Impair ERG and MAFB Binding. Journal of dental research 15 34852650
2020 ERG-Mediated Coregulator Complex Formation Maintains Androgen Receptor Signaling in Prostate Cancer. Cancer research 15 32934023
2015 ERG expression in prostate cancer: biological relevance and clinical implication. Journal of cancer research and clinical oncology 15 26711283
2014 ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer. Molecular cancer research : MCR 14 25344575

Missed literature

Know a paper Affinage missed for ERG? Flag it for the maintainers and the community.

No submissions yet.